Combating antimicrobial resistance: policy recommendations to save lives - Wikidata - awgldk - TriplyDB

Combating antimicrobial resistance: policy recommendations to save lives

Combating antimicrobial resistance: policy recommendations to save lives

http://www.wikidata.org/entity/Q24632857

about

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics How to educate prescribers in antimicrobial stewardship practices Strategies and molecular tools to fight antimicrobial resistance: resistome, transcriptome, and antimicrobial peptides The global threat of antimicrobial resistance: science for intervention Inhaled Antibiotics for Gram-Negative Respiratory Infections Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection The Widespread Presence of a Multidrug-Resistant Escherichia coli ST131 Clade among Community-Associated and Hospitalized Patients Reducing Antibiotic Use for Young Children with Intussusception following Successful Air Enema Reduction Routine use of microbial whole genome sequencing in diagnostic and public health microbiology Bacteriophages from ExPEC Reservoirs Kill Pandemic Multidrug-Resistant Strains of Clonal Group ST131 in Animal Models of Bacteremia Trends of Antibiotic Consumption in Korea According to National Reimbursement Data (2008-2012): A Population-Based Epidemiologic Study [Release of antibiotics into urban wastewater: A secondary-data based analysis for the input assessment using the city of Dresden as an example].A Systematic Review of Quality Indicators for Appropriate Antibiotic Use in Hospitalized Adult Patients.Antibiotic judo: working gently with prescriber psychology to overcome inappropriate use.Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network.Leveraging antimicrobial stewardship into improving rates of carbapenem-resistant Enterobacteriaceae The future of antibiotics Estimating the disease burden of methicillin-resistant Staphylococcus aureus in Japan: Retrospective database study of Japanese hospitals Transferrin iron starvation therapy for lethal bacterial and fungal infections.Antibiotics and bacterial resistance in the 21st century.The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett.Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS).Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes Competition studies confirm two major barriers that can preclude the spread of resistance to quorum-sensing inhibitors in bacteria Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.Primary care treatment guidelines for skin infections in Europe: congruence with antimicrobial resistance found in commensal Staphylococcus aureus in the community.Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem.'Old' antibiotics for emerging multidrug-resistant bacteria The evolution of the regulatory framework for antibacterial agents Efficacy of admission screening for extended-spectrum beta-lactamase producing Enterobacteriaceae Antimicrobial co-resistance patterns of gram-negative bacilli isolated from bloodstream infections: a longitudinal epidemiological study from 2002-2011.Treatment of bloodstream infections in ICUs Antimicrobial stewardship - can we afford to do without it?Novel quorum-quenching agents promote methicillin-resistant Staphylococcus aureus (MRSA) wound healing and sensitize MRSA to β-lactam antibiotics.Changes in antimicrobial use prevalence in China: results from five point prevalence studies.Evolution and emergence of infectious diseases in theoretical and real-world networks.In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.

P2860

Q24601746-1F4D3605-A6AB-476D-9DD0-94D03C815D42 Q26783545-F2523ADD-071F-4026-BCF2-6E7EDB74DF69 Q26851384-2B3A359A-8FCC-4620-9FEC-5C833FE568B1 Q26861137-C6F7AA82-3BE0-4762-B3A8-01F026274459 Q28083609-05342F13-C777-429D-898D-06831C3F8997 Q28386160-7BBA1794-AE00-46A0-8FDD-6A0CE9CBE0EB Q28478751-D0FB019C-843B-40DB-AB94-AA10E9A3D675 Q28550451-C454E97D-FE94-4E3F-ADF1-C6E8F9CD54D9 Q28550971-B5F5EB21-FD8C-4E94-94DF-AE72021ABB73 Q28728617-16D635FD-B009-476C-834C-C1DB848DDEE5 Q30401003-D6CD4230-29A6-4F77-9A9C-C810D9AB3386 Q31025566-32D31C5C-AFFF-48A4-A3A8-DE53CC1F75EC Q31030674-6F50AFA7-FE91-4151-AADB-4FB0B2E90009 Q33564279-0864DD2D-CA0C-4901-83D0-469DBF14ED47 Q33782290-86FD2613-C71F-4C07-95EB-36FDA0C92A45 Q33798238-B6BFC5C8-F478-4AE0-9258-E7EE15AA3396 Q33816217-1A13DD80-2EAA-49BE-9754-E97278AFF0DE Q33821520-1976FD72-1EBC-4822-8C0A-C7B7068664F8 Q33842265-E5B63CE5-AD23-415B-89E9-1691BB666AAB Q33883214-7FB19A03-9000-412B-B441-5DCE2D045A22 Q34156349-E4AEB036-0C0B-473C-B54A-A43257464EAA Q34249480-B63D8E92-03D0-4AB3-92B8-7A5364E4FAF2 Q34261329-70AB2581-3BDD-4A3C-BFCB-8DE9095632DB Q34320945-8F3C072B-4903-44D3-A22A-405A1EC47AC0 Q34361104-F1543A1E-7077-40DF-9019-A2786259E899 Q34366895-E7EB5C75-8070-465D-9891-F0F188F5A8B0 Q34447679-07A225F1-9650-4B79-B348-19255A9C954F Q34451829-0C275787-2CCA-4DE5-A54E-B976E71FBF8C Q34481243-39D76958-ED1C-4EE2-AF76-52338D7E9DCF Q34514304-47D619C8-AB6A-4A5C-A9A7-53AC0A0F794C Q34565772-7A1C4255-4BCF-4329-9898-A3E0A04B8D9F Q34693386-EC6EA71F-A875-45F9-9B96-FE57F34887C7 Q34701924-3299B4FF-313A-4AA9-9202-B96FAFC989B3 Q34875817-22F2F7AE-7018-4DBE-B399-EE14831C9D65 Q34896896-C79034C7-D526-4914-BFD1-E5801047AAA5 Q35023684-2197AE13-BA10-49CE-BD40-B88002B6176A Q35076859-CA32C84A-E63C-422A-9ADE-170E6FCE646C Q35077730-91B701CB-CBDF-411C-B666-5DB5E566F74F Q35104835-F69190E0-F76A-4FF3-A590-5F44C7134DC1 Q35105932-B6D72556-3AB3-45EA-9703-A5B626160442

P2860

Combating antimicrobial resistance: policy recommendations to save lives

http://www.wikidata.org/entity/Q24632857

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Combating antimicrobial resistance: policy recommendations to save lives

@ast

Combating antimicrobial resistance: policy recommendations to save lives

@en

Combating antimicrobial resistance: policy recommendations to save lives

@nl

type

label

Combating antimicrobial resistance: policy recommendations to save lives

@ast

Combating antimicrobial resistance: policy recommendations to save lives

@en

Combating antimicrobial resistance: policy recommendations to save lives

@nl

prefLabel

Combating antimicrobial resistance: policy recommendations to save lives

@ast

Combating antimicrobial resistance: policy recommendations to save lives

@en

Combating antimicrobial resistance: policy recommendations to save lives

@nl

P1433

Q24632857-DD94A72C-EF6D-4D5B-BB69-7FFA1B075139

P1476

Q24632857-1BD2E874-56F2-4B8F-BC46-C11AD8A15AF7

P2093

Q24632857-05CAC8C8-5B55-4A66-9EE2-0EB582F1BCB8

Q24632857-068C3C23-C296-4FC5-93E9-0EA936FBE7EF

Q24632857-1ADA97B4-FA73-44FD-A9E5-96905D793F8C

Q24632857-30FC5F18-A529-4740-8CFF-9EE51B0B8FC2

Q24632857-4499B450-37CF-47CC-8E44-F2ED792C039F

Q24632857-62CCFA6E-E7B6-4644-890C-5AB5A6C174FC

Q24632857-A5F94BB1-5E09-4F47-B967-7FA697C288FF

Q24632857-C932D1EB-8177-48A8-A5C5-80641BFAA722

Q24632857-D8D07F0C-4462-4515-B669-9527ABFAFE23

Q24632857-EDC66FE3-0301-429B-9C47-F7F1B3909C25

P2860

Q24632857-0508BEF4-8772-4DA3-913B-78E21AECC2C3

Q24632857-0544BFF6-9FAC-4CA7-8023-ACC7646A8F4A

Q24632857-094DA2E1-8ADD-4CC0-8490-3B5B0FD97599

Q24632857-0F5756C9-A9AC-4EEE-B268-D1914082CB5E

Q24632857-14D68F43-6DB7-4A99-9DCD-A00FFE54674B

Q24632857-1871D85C-A875-4F4E-8975-EE0805F4A2DE

Q24632857-1883032B-4D93-43EE-82B6-C4D54817281C

Q24632857-22BAE87F-E007-4E24-AAE9-5B030D02B975

Q24632857-264C3716-D7B9-4C55-A074-C3F35F667AF4

Q24632857-2AE37B57-C07F-4B69-8AED-25A1D0AAF959

P304

Q24632857-0EA04B2D-5BD2-42A7-A389-2441E50BC348

P31

Q24632857-845E13A1-36CD-4F48-82F8-4E2694110D81

P3181

Q24632857-05BC9A6F-B32F-4BBA-BCEC-9DB4A8726BC4

P356

Q24632857-AF215CE4-A78C-4045-8F37-13F2AC4548C4

P407

Q24632857-3EBD5547-AF5A-475B-8052-619A5D0B83A4

P433

Q24632857-CD31440A-1424-4E4D-B236-CDBE47B0F0E6

P478

Q24632857-5C4F462A-F8D1-4945-860E-D3ED8DA70BAC

P50

Q24632857-43DA8D0E-E6D9-484F-8C29-694621458207

Q24632857-A37D304A-D1A0-4E8F-A51A-73F47B13D01B

Q24632857-F1AC29EF-3E38-40A8-85BA-6AA4DC2D8948

P577

Q24632857-BF53D090-0144-43E4-9B9A-C51CC4E7D530

P5875

Q24632857-DCDA59E5-DB3D-417A-BFAE-AF1426599787

P698

Q24632857-330147DE-A9F0-47EC-B64D-C32862B87E52

P921

Q24632857-204FB558-6CFB-4D95-9305-ECC5251F7B91

Q24632857-3FE5D373-105E-41A2-9556-8F567975B407

Q24632857-96A51078-4EE6-4C78-B35B-0CDF3ACDE1A2

P932

Q24632857-1FD9BF17-05DC-47CB-819B-F0350094C528

P3181

P356

P1433

Clinical Infectious Diseases

P1476

Combating antimicrobial resistance: policy recommendations to save lives

@en

P2093

Barry I Eisenstein

http://www.w3.org/2001/XMLSchema#string

Brad Spellberg

http://www.w3.org/2001/XMLSchema#string

David N Gilbert

http://www.w3.org/2001/XMLSchema#string

David Schwartz

http://www.w3.org/2001/XMLSchema#string

Edward Septimus

http://www.w3.org/2001/XMLSchema#string

Fred C Tenover

http://www.w3.org/2001/XMLSchema#string

Helen W Boucher

http://www.w3.org/2001/XMLSchema#string

John Rex

http://www.w3.org/2001/XMLSchema#string

John S Bradley

http://www.w3.org/2001/XMLSchema#string

L Barth Reller

http://www.w3.org/2001/XMLSchema#string

P2860

Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007

Resistance in Nonfermenting Gram-Negative Bacteria: Multidrug Resistance to the Maximum

Duration of antibacterial treatment for uncomplicated urinary tract infection in women

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

Estimating health care-associated infections and deaths in U.S. hospitals, 2002

The Tragedy of the Commons

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

The tragedy of the commons. The population problem has no technical solution; it requires a fundamental extension in morality

Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE

Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials.

P304

S397-428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1659014

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/CID/CIR153

http://www.w3.org/2001/XMLSchema#string

P407

P433

Supplement 5

http://www.w3.org/2001/XMLSchema#string

P478

52 Suppl 5

http://www.w3.org/2001/XMLSchema#string

P50

Martin J. Blaser

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51033862

http://www.w3.org/2001/XMLSchema#string

P698

21474585

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

antibiotic resistance

antimicrobial resistance

P932

3738230

http://www.w3.org/2001/XMLSchema#string